Chemomab Therapeutics Ltd. Stock Price

NasdaqCM:CMMB Community·US$17.8m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
1 Fair Values set on narratives written by author

Create a narrative

CMMB Share Price Performance

US$3.38

-1.66 (-32.94%)

US$3.38

-1.66 (-32.94%)

US$3.38

Thu, 16 Oct 25

Share PriceUS$3.38

CMMB Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks

0 Rewards

View Full Analysis

Chemomab Therapeutics Ltd. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -2.29
: 0%
: 0%
: 0%

View Full Analysis

About CMMB

Founded: 2011
Employees: n/a
CEO: Adi George
WebsiteView website: www.chemomab.com

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.